Orticumab
Monoclonal antibody
- none
- 1314241-10-5
- none
- 2O892R8U24
Orticumab (INN) is a human monoclonal antibody that is used as an anti-inflammatory agent and binds to oxLDL. It acts as an immunomodulator.[1]
References
- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- v
- t
- e
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems
Human |
|
---|---|
Humanized |
|
Human |
|
---|
Human |
|
---|---|
Mouse |
|
Chimeric | |
Humanized |
Human | |
---|---|
Humanized |
Humanized |
---|
Human | |
---|---|
Humanized |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e